Last reviewed · How we verify
NCT05669586
Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer
Phase 2 trial testing Antitumor therapy guided by organoid drug sensitivity test in Lung Cancer in 50 participants. Currently enrolling.
31 May 2024
Quick facts
| Lead sponsor | Affiliated Hospital of Jiangnan University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 February 2023 |
| Primary completion | 31 May 2024 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Antitumor therapy guided by organoid drug sensitivity test — full drug profile →
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Organoid — all drugs for Organoid →
Sponsor
Affiliated Hospital of Jiangnan University
Who can join
18 and older, any sex, with Lung Cancer or Organoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, single-arm, open and exploratory clinical study. The purpose of this study was to evaluate the consistency and accuracy of the organogenic (PDO) model for patients with lung cancer, to predict the clinical efficacy of anticancer drugs, and to speculate and select personalized treatment regiments for patients with lung cancer who are resistant to multi-line standard therapies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274 -
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735 -
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656 -
Tumor-derived systems as novel biomedical tools-turning the enemy into an ally.
Desai N, Katare P, Makwana V, Salave S, et al · · 2023 · cited 20× · PMID 37946275 · DOI 10.1186/s40824-023-00445-z -
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure.
Kang DH, Lee J, Im S, Chung C. · · 2024 · cited 9× · PMID 39682183 · DOI 10.3390/cancers16233996 -
Modeling Liver Development and Disease in a Dish.
Iqbal W, Wang Y, Sun P, Zhou X. · · 2023 · cited 4× · PMID 37958904 · DOI 10.3390/ijms242115921 -
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104 -
Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects.
Li R, Wu Y, Zheng Z, Zhou F, et al · · 2026 · cited 1× · PMID 41503026 · DOI 10.1002/mco2.70575
Verify or expand the search:
- PubMed search for NCT05669586
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Affiliated Hospital of Jiangnan University trials
Trials by the same sponsor.
- NCT07023861 — The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies · EARLY_PHASE1 · enrolling by invitation
- NCT07023848 — PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors · EARLY_PHASE1 · enrolling by invitation
- NCT07162779 — Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients · NA · enrolling by invitation
- NCT06448975 — An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease · NA · recruiting
- NCT06723665 — The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05669586 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Jiangnan University
- Last refreshed: 19 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05669586.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing